Pfizer buys cancer biotech firm Seagen for $US43 billion
2023-03-16
US pharmaceutical giant Pfizer has announced a deal to buy biotech firm Seagen, which specialises in innovative cancer treatment, for $US43 billion ($A64.6 billion). Pfizer is offering $US229 ($344) per share in cash, and the companies expect to complete the transaction later this year or in early 2024, they saidContinue Reading
